Cambridge Antibody Technology Group Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jongmans who started this subject	4/21/2003 11:07:38 AM
From: nigel bates	of 625

Progress on LymphoStat-B: Message 18864358 ...HGSI announced today that results from a Phase 1 clinical trial demonstrate that LymphoStat-B(TM) (a human monoclonal antibody to B-lymphocyte stimulator, BLyS(TM)) is well tolerated and biologically active in patients with systemic lupus erythematosus. Human Genome Sciences plans to initiate Phase 2 clinical trials of LymphoStat-B for the treatment of lupus and for the treatment of rheumatoid arthritis in 2003. The company also announced that LymphoStat-B has received a Fast Track Product designation for the treatment of systemic lupus erythematosus...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next